{"entity":{"id":"nct01368276","kind":"trial","name":"An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma","aka":[],"tldr":"A phase 3 trial of Talimogene laherparepvec in Melanoma, run by BioVex Limited, completed.","summary":"An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma is a phase 3 interventional study registered as NCT01368276 by BioVex Limited, with 31 participants recorded, started 2010-10 and reaching its primary completion in 2014-09. Interventions recorded: Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). Conditions recorded: Melanoma.\n\nLinked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01368276","url":"https://clinicaltrials.gov/study/NCT01368276"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["talimogene-laherparepvec"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01368276","phase":"3","setting":"An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05","sponsor":"BioVex Limited","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01368276/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}